Dr. Joel Schlessinger’s article on AbobotulinumtoxinA for the treatment of glabellar lines was featured on MDLinx.com
Dr. Joel Schlessinger’s recent article titled “Long-Term Safety Of AbobotulinumtoxinA For The Treatment Of Glabellar Lines: Results From A 36-Month, Multicenter, Open-Label Extension Study” was featured on MDLinx.com. Originally published in Dermatologic Surgery, this study was ranked by a team of physician editors as no. 6 on MDLinx’s dermatology website.
Studies like Dr. Joel Schlessinger’s make a difference in the healthcare industry.
MDLinx connects patients to scholarly articles and peer-reviewed journals from the medical industry. Professionals can also use this website as a tool to keep up with the latest research. Clinical articles like Dr. Joel Schlessinger’s provide a wealth of knowledge for both patients and professionals.
The website also gave Dr. Joel Schlessinger the opportunity to respond to his article, offering a personal view on how the study’s findings have impacted the field of dermatology.
“AbobotulinumtoxinA (Dysport) continues to be an interesting and useful addition to the armamentarium of botulinum toxins available,” Dr. Joel Schlessinger said. He added that the study is “helpful for prospective patients with lingering concerns” because it improves the safety profile of neurotoxins.
As an expert in the fields of dermatology and cosmetic surgery, Dr. Joel Schlessinger participates in a number of studies each year.
Dr. Joel Schlessinger frequently participates in studies centered on new drug and treatment options. Are you interested in participating in a local research study with Dr. Joel Schlessinger? If you live in the Omaha area, visit our website for more information on our current studies.